Kiadis Pharma NV has secured its first major deal for a technology that involves the use of natural killer (NK) cells to detect and kill cancer. Under a collaboration with Sanofi SA, Kiadis will out-license rights to a preclinical asset for multiple myeloma as well as rights to two other undisclosed preclinical programmes.
In exchange, Sanofi will make an upfront payment to Kiadis of €17.5 million as well as commit to potential milestone payments of up to €857.5 million. Kiadis will also receive up to low double-digit royalties on the sales of any approved products.